PTC Therapeutics

PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize

Retrieved on: 
Wednesday, July 19, 2023
PTC Therapeutics, University, Ataluren, Culture, PTC, Messenger, Genetics, Knowledge, Dentistry, Rare, Therapy, Management, Neuroscience

SOUTH PLAINFIELD, N.J., July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.

Key Points: 
  • SOUTH PLAINFIELD, N.J., July 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Allan Jacobson, Ph.D., co-founder of PTC and member of the Board of Directors, was presented the 2023 Gruber Genetics Prize for his work in identifying and describing the mechanism of nonsense-mediated mRNA decay today in a ceremony in Australia.
  • "On behalf of PTC's Board of Directors and leadership team we congratulate Allan on receiving this prestigious award and recognition," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.
  • The Gruber International Prize Program honors individuals in the fields of Cosmology, Genetics and Neuroscience, whose groundbreaking work provides new models that inspire and enable fundamental shifts in knowledge and culture.
  • Dr. Jacobson shares the prize with Lynn Maquat, Ph.D., a molecular biologist at the University of Rochester School of Medicine and Dentistry.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Wednesday, July 19, 2023
Workforce, LLP, Employment, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Patient, United, Pomerantz, Therapy, Private investigator

NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).

Key Points: 
  • NEW YORK, July 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer

Retrieved on: 
Monday, July 17, 2023
Ferring Pharmaceuticals, PTC Therapeutics, University, PTC, Perella Weinberg Partners, Barclays, Patient, ESCP Business School, CFO, Knowledge, Pierre, Therapy, Family, Pharmaceutical industry, Science

SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO).

Key Points: 
  • SOUTH PLAINFIELD, N.J., July 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial Officer (CFO).
  • Mr. Gravier brings more than 17 years of experience as an investment banker, venture capitalist and scientist to PTC.
  • Most recently, Pierre was a managing director in the healthcare group of Perella Weinberg Partners, a leading independent global advisory firm.
  • "We are incredibly excited to have Pierre as part of PTC's leadership team," said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics.

PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin

Retrieved on: 
Tuesday, July 11, 2023
PKU, PTC, Hospital, PTC Therapeutics, Therapy, MD, Q&A, University Children's Hospital Basel, University Children Clinical Hospital in Białystok, Chair, University Medical Center, Pharmaceutical industry, Online shopping, Pediatrics

SOUTH PLAINFIELD, N.J., July 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the current therapeutic and commercial landscape with an expert key opinion leader.

Key Points: 
  • SOUTH PLAINFIELD, N.J., July 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), announced today that the company will provide a virtual presentation on PKU including discussion of the current therapeutic and commercial landscape with an expert key opinion leader.
  • In addition, the company will discuss the sepiapterin clinical program followed by a Q&A session.
  • Presenters will include Ania C. Muntau, MD, Professor of Pediatrics, Chair, University Children's Hospital, University Medical Center, Hamburg Eppendorf, Germany, and PTC senior management.
  • The webcast conference call can be accessed on the Investor section of the PTC website at https://ir.ptcbio.com/events-presentations .

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Sunday, July 9, 2023
Workforce, LLP, Employment, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Patient, United, Pomerantz, Therapy, Private investigator

NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).

Key Points: 
  • NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Sunday, July 2, 2023
Workforce, LLP, Employment, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Patient, United, Pomerantz, Therapy, Private investigator

NEW YORK, July 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).

Key Points: 
  • NEW YORK, July 02, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk

Retrieved on: 
Friday, June 30, 2023
Biotechnology, Consumer, Health, Pharmaceutical, Children, SMN, SMA, Disease, PTC Therapeutics, SMN2, PTC, Aes, Roche, Cure, Medicine, ROG, RO, Bayley Scales of Infant Development, Walking, Patient, Infant, Ageing, Upper respiratory tract infection, Therapy, Pneumonia, Mouth, UCL Great Ormond Street Institute of Child Health, Birth control, Pharmaceutical industry, Genentech, Fever, Risdiplam

After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.

Key Points: 
  • After four years of treatment with Evrysdi, many of the babies, now young children, continued to improve their ability to sit, stand and walk without support.
  • All the Evrysdi-treated children who were alive at the time of the primary analysis were still alive at month 48.
  • Additionally, the majority of infants maintained their ability to feed by mouth and swallow up to month 48.
  • Genentech leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

Parent Project Muscular Dystrophy Hosts 29th Annual Conference in Dallas, Texas

Retrieved on: 
Wednesday, June 28, 2023
Learning, Therapy, PTC Therapeutics, Duchenne muscular dystrophy, Gene, Furlong, Pfizer, Life, Face, Breakout box, Parent, Workplace, Becker muscular dystrophy, Research, Grandparent, Brain, Respiratory therapist, Behavior, Senior counsel, Genetic counseling, Sarepta Therapeutics, App, Sibling, Physician, PPMD, Motivation, Cardiology, Caregiver, Conference, News, Platinum, Nursing, Pharmaceutical industry, Birth control, Residential care, Music, Video game, Becker, Duchenne

WASHINGTON, June 28, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host their 2023 Annual Conference in Dallas, Texas, June 29 - July 1. Each year, the Duchenne community gathers to learn about the latest progress in the fight to end Duchenne and connect with leading experts. Now in its 29th year, after introducing a hybrid format featuring both in-person and virtual participation options in 2022, PPMD's Annual Conference engages more of the Duchenne community than ever before.  

Key Points: 
  • WASHINGTON, June 28, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , will host their 2023 Annual Conference in Dallas, Texas, June 29 - July 1.
  • Now in its 29th year, after introducing a hybrid format featuring both in-person and virtual participation options in 2022, PPMD's Annual Conference engages more of the Duchenne community than ever before.
  • PPMD's 2023 Annual Conference agenda will feature stories from multiple keynote speakers, and interactive discussion panels addressing comprehensive, multi-dimensional approaches to care for Duchenne.
  • Becker-specific breakout sessions, including discussions on neuromuscular care, cardiology, genetic counseling, and physical therapy, as well as updates about emerging therapies for Becker muscular dystrophy.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

Retrieved on: 
Monday, June 26, 2023
Workforce, LLP, Employment, PTC Therapeutics, Friedreich's ataxia, PTC, Research, Patient, United, Pomerantz, Therapy, Private investigator

NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).

Key Points: 
  • NEW YORK, June 25, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether PTC and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

US Cell & Gene Therapy Market Report 2023-2028: Industry Expected to Grow at a CAGR of 41.25% - ResearchAndMarkets.com

Retrieved on: 
Friday, June 23, 2023
Health, Pharmaceutical, Spark Therapeutics, Amgen, Gilead Sciences, PTC Therapeutics, BioMarin Pharmaceutical, Cancer, Organogenesis, Telephone numbers in South Africa, Bristol Myers Squibb, AAV, Stem cell, Food and Drug Administration Safety and Innovation Act, CAR, CDMO, Novartis, Blood, Cell, Conditional sentence, Growth, Rare, FDA, Therapy, Food, Vaccine, Pharmaceutical industry, Tisagenlecleucel

This report offers market size & forecast data for the cell & gene therapy market in the US.

Key Points: 
  • This report offers market size & forecast data for the cell & gene therapy market in the US.
  • The report covers commercial cell & gene therapy products, such as conventional cell therapies, CAR-T cell therapies, gene therapies, cell-based immunotherapies, and oncolytic virus therapies.
  • This report provides a comprehensive and current market scenario of the US cell & gene therapy market, including the US cell & gene therapy market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present cell and gene therapy market and its market dynamics for 2023-2028 in the US.